Radioiodine uptake in normal female breasts and liver of a patient with differentiated thyroid cancer imaged by whole body scanning.

Abstract

511 AYOUNG WOMAN with papillary thyroid cancer treated with total thyroidectomy, received an ablative dose (3000 MBq) of 131I. Thyroxine had been withdrawn for 4 weeks. A wholebody scan was performed 8 days after the ablative dose of 131I. The scan (Fig. 1) shows uptake in the thyroid bed caused by thyroid remnant, diffuse uptake in the liver, and uptake in both breasts. Post-131I therapy scans are routinely performed in our center, because the diagnostic accuracy is greater than after a conventional tracing dose (70–150 MBq) of 131I (1). Uptake in the breasts of female patients undergoing 131I whole-body scanning is occasionally seen in post-therapy scans, and may be misinterpreted as being pathological. Diffuse hepatic uptake is also common in the presence of functioning thyroid remnant, and represents hepatic metabolism of iodoproteins, which may be mistaken for metastases. The normal human female breast epithelium expresses the sodium iodide symporter (2,3) and can also organify iodide. The uptake of iodide by breast tissue is currently being explored as a potential therapy for breast cancer (4).